Issues
-
Cover Image
Cover Image
About the Cover
Although T cells infiltrate melanomas, they usually fail to clear the tumor. Plasmacytoid DCs (PDCs) can regulate T-cell function and, in addition, can eliminate melanomas by TLR-mediated mechanisms. Vescovi et al. show that infiltration by PDCs occurs early in primary cutaneous melanoma and their localization is at the invasive margin, where the PDCs can interact with CD8+ T cells. However, in advanced and metastatic disease, PDCs do not infiltrate into tumor tissues and PDCs in circulation are reduced. This is due to a collapse of the PDC compartment during cancer progression, caused by soluble factors in the melanoma secretome that lead to PDC death and impaired differentiation from progenitor cells. These data highlight that rescuing PDCs could help in inducing antitumor responses. Read more in this issue on page 12. Original image is a primary cutaneous melanoma with little infiltration of PDCs from Fig. 1H. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Meeting Report
Cancer Immunology Miniature
Research Articles
Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer
Correction
Acknowledgment to Reviewers
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.